生物标志物
免疫疗法
医学
肿瘤科
癌症
养生
癌症研究
临床试验
癌症免疫疗法
免疫检查点
内科学
生物
生物化学
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-11-22
卷期号:: OF1-OF1
被引量:1
标识
DOI:10.1158/2159-8290.cd-nb2023-0090
摘要
Abstract New trial data confirm the potential of tertiary lymphoid structures to serve as a predictive biomarker of responsiveness to an immune checkpoint inhibitor–based drug regimen. According to study results presented at the Society for Immunotherapy of Cancer Annual Meeting, treatment with a PD-L1–targeted agent plus a multikinase inhibitor with anti-angiogenic activity yielded clinical responses in patients with TLS-positive tumors, even in cancer types typically considered resistant to checkpoint inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI